Roche Holding (RHHBY) Stock Research

Friday

Roche just upgraded at Morgan Stanley, here's why

RHHBY

Aug 7, 4:17 AM

Thursday

Roche expands cyclospora testing portfolio to support US public health response

RHHBY

Aug 6, 8:42 AM

Tuesday

Labcorp launches FDA-approved PTEN companion diagnostic for prostate cancer

Aug 4, 7:12 AM

Monday

Genprex announces collaboration with Roche Diagnostics

Aug 3, 7:06 AM

Over a week ago

Roche announces EMA's CHMP recommended approval of Susvimo

RHHBY

Jul 24, 8:45 AM

Roche receives FDA 510(k) clearance for cobas BV/CV assay

RHHBY

Jul 24, 8:31 AM

Roche confirms FY26 outlook

RHHBY

Jul 23, 6:10 AM

Roche reports 1H group sales CHF 30.4B vs. CHF 30.9B last year

RHHBY

Jul 23, 6:09 AM

Trump Trade: U.S. to impose 100% tariff on imported generic drugs

+27

Jul 22, 10:06 AM

Trump to set 100% tariff on generic drugs brought into U.S. starting in 2028

+10

Jul 21, 7:01 PM

MaxCyte enters technology license partnership with Genentech

Jul 21, 8:43 AM

Roche names Dan Malarek as President and CEO of Roche Diagnostics North America

RHHBY

Jul 20, 8:21 AM

Genentech granted priority review for Gazyva sBLA by FDA

RHHBY

Jul 15, 5:36 AM

Nurix Therapeutics price target raised by $3 at RBC Capital, here's why

Jul 10, 8:43 AM

Nurix Therapeutics price target raised by $2 at Truist, here's why

Jul 10, 8:41 AM

Roche receives CE Mark for blood test to identify tuberculosis infection

RHHBY

Jul 9, 5:13 AM

Roche just downgraded at HSBC, here's why

RHHBY

Jul 6, 5:48 AM

Genentech announces Krascendo 1 study met primary, key secondary endpoint

RHHBY

Jul 2, 5:21 AM

AI Daily: Amazon’s AWS commits $1B toward new unit

+10

Jun 30, 1:48 PM

Anthropic takes aim at pharma industry with Claude Science, STAT reports

Jun 30, 1:13 PM

Genentech announces priority review for Enspryng

RHHBY

Jun 30, 5:36 AM

Roche announces launch of AXELIOS 1, a next-gen sequencing platform

RHHBY

Jun 29, 6:56 AM

Sanofi investors likely to view new R&D head as a positive, says BofA

Jun 22, 9:16 AM

Nurix Therapeutics price target raised by $7 at Baird, here's why

Jun 18, 6:24 AM

Genentech says FDA accepts sBLA for for Lunsumio VELO

RHHBY

Jun 18, 6:03 AM

Leading R&D Prowess: Roche consistently invests heavily in research and development, resulting in a robust pipeline of innovative drugs and diagnostics, particularly in oncology, neuroscience, and immunology.

Dominant Oncology Market Position: Roche holds a leading global market share in oncology, with several blockbuster drugs and a strong heritage in cancer treatment, making it a preferred partner for healthcare providers.

Integrated Pharma and Diagnostics: Its unique combination of pharmaceutical and diagnostic divisions allows for a holistic approach to personalized healthcare, creating synergies in drug discovery, development, and patient stratification.

Clinical Development and Regulatory Approval Risks: The success of Roche's future growth relies on its ability to discover, develop, and obtain regulatory approval for new pharmaceutical and diagnostic products. Failures in clinical trials or delays in regulatory submissions can significantly impact the pipeline and future revenue.

Patent Expiry and Biosimilar/Generic Competition Risks: Key pharmaceutical products facing patent expiration are exposed to competition from lower-priced biosimilars and generic versions. This erosion of market share can lead to substantial revenue declines for established blockbusters.

Pricing Pressure and Healthcare Policy Risks: Global healthcare systems are under increasing pressure to contain costs, leading to demands for lower drug prices and more stringent reimbursement policies. Government reforms and payer negotiations can negatively impact profitability and market access for Roche's products.